Who we are
BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.
BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System and beyond, based on 20 years of translational research. Its main goal is to enable a really personalized medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.
More specifically, great attention is being placed towards diminishing risks for patients through minimal invasive solutions which will enable very substantial cost reductions for the Health Systems.
The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. The identification of biomarkers to evaluate, predict and diagnose the risk of transplant rejection will provide clinicians with ways of better anticipating and adapting their patients’ treatment. The goal being to reduce as much as possible numerous secondary effects. BioMAdvanced Diagnostics Tests will provide predictive scores and will be easily integrated into diagnostic and standard treatment protocols, easy to use by medical practitioners.
BioMAdvanced Diagnostics is incubated by Atlanpole and supported by SATT Ouest Valorisation.
In September 2022, the company announced a round of seed investment, raising 1,7 million euros, followed by a 2nd round of Seed in June 2023.
As of February 2024, BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018.
Our Founders
Frédéric Pette – Cofounder
President and CEO
20 years of MedTech experience as an international General Manager having led multidisciplinary teams on all continents dealing with businesses ranging from a nascent stage to global division of $1Bn turnover.
Nicolas Bouler – Cofounder
Chief Development Officer
20 years of experience in complex medical devices (Implantable Class III), including R&D, regulatoray affairs, Quality management systems, Product Management, Clinical Evaluation, and Post market Surveillance in international companies and startups.
Dr. Sophie Brouard – Cofounder
Chief Scientific Advisor
Vice Director of the CRTI (Centre de Recherche en Transplantation et Immunologie, Université de Nantes, Inserm), Director of research and Group leader in immunology/transplantation (CNRS, INSERM), has published over 230 articles and reviews, co-inventor of 13 patents, co-founded two other companies, has earned the Innovation medal 2020 of the CNRS and the Bronze medal of the CNRS.
Dr. Richard Danger – Cofounder
Chief Technology Advisor
Research associate (CHU Nantes, INSERM) at the CRTI ( Centre de Recherche en Transplantation et Immunologie, Université de Nantes, Inserm), 2016 Marie Sklodowska-Curie H2020 Fellow, has published over 42 articles and reviews, co-inventor of 4 patents.
Pr. Jean-Michel Bouler – Cofounder
Chief Prospective Advisor
Director of the CEISAM Lab (Chimie, Interdisciplinarité, Synthèse, Analyse, Modélisation, Université de Nantes, CNRS, INSERM), Director of research (CNRS, INSERM), has published over 150 articles and reviews, co-inventor of 9 patent families, co-founded two other companies.
Our Scientific Advisory Board
External Advisors
They Support us
Our Investors
